Form 10-Q · Quarterly report
Avery Dennison 10-Q, filed Aug 4, 2026
- Filed
- CIK
- 0000008818
- Accession no.
- 0000008818-26-000131
Summary
Avery Dennison reported second-quarter 2026 net sales of $2.46 billion, up 11% year over year, and first-half net income of approximately $372 million, up from roughly $355 million a year earlier. The company recorded $34.7 million in restructuring charges in the first half tied to cutting about 600 positions, and reported adjusted free cash flow of $469.8 million for the period.
Key points
- Second-quarter net sales were $2.46 billion, up 11% from $2.22 billion a year earlier, with organic sales change of 8%.
- Net income for the first six months of 2026 was approximately $372 million, up from approximately $355 million in the same period of 2025.
- The company recorded $34.7 million in restructuring charges in the first half of 2026 tied to the reduction of about 600 positions and asset impairments.
- Adjusted free cash flow for the first six months of 2026 was $469.8 million, up from $135.8 million a year earlier.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Management’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, should be read in conjunction with the accompanying unaudited Condensed Consolidated Financial Statements and related notes thereto. NON-GAAP FINANCIAL MEASURES We report our financial results in conformity with accounting principles generally accepted in the United States of America, or GAAP, and also communicate with investors using certain non-GAAP financial measures. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.